相关实验视频
Updated: Jul 28, 2025

Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
一个试点的药物遗传学研究通道阻断剂治疗双极性躁狂
Miao Li1, Ning Yuan2, John I Nurnberger3
1Center for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, and Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, China.
通道基因中的遗传变异可能预测接受通道阻断剂 (CCB) 的双相情感障碍 (BD) 患者的治疗反应. 在躁狂发作期间,某些CACNA1B基因变异对CCB附加疗法的反应更好.
科学领域:
- 神经科学是一个神经科学.
- 药物遗传学 药物遗传学
- 精神病学是一个精神病学.
背景情况:
- 通道基因中常见的遗传变异与双相情感障碍 (BD) 易感性有关.
- 通道阻断剂 (CCB) 已显示出改善一些BD患者情绪稳定的潜力.
研究的目的:
- 调查具有特定通路遗传风险变异的患者在躁狂发作期间从CCB治疗中显示出差异性益处.
- 探索单核酸多态性 (SNPs) 在通道基因中对双相躁狂中CCB治疗反应的预测价值.
主要方法:
- 一项试点研究涉及50名患有躁狂发作的双相情感障碍患者住院治疗.
- 患者接受了CCB的附加治疗,并确定了他们的基因型.
- 在治疗前和治疗后评估了年轻狂热评分表 (YMRS) 评分.
主要成果:
- 额外的CCB治疗导致YMRS得分显著下降.
- 在CACNA1B基因 (rs2739258和rs2739260) 中的两个内基变异与治疗结果有关.
- 与AA或GG基因型相比,rs2739258/rs2739260的AG等位基因携带者对CCB补充疗法表现出更好的反应.
结论:
- 通道基因中的SNP可能作为预测剂,用于预测双极性躁狂中添加CCB治疗的反应.
- 通道基因可能在双相情感障碍的治疗反应机制中发挥作用.
更多相关视频
10:20Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
10:01High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
Published on: March 31, 2022
相关概念视频
Mania and Antimanic Drugs: Overview
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antihypertensive Drugs: Action of Calcium Channel Blockers
Bipolar Disorder